Chief Accounting Officer files intent to sell $7.4M in shares ahead of departure
NAMS has more than doubled off its 52-week low of $16.785.
Summary
NewAmsterdam Pharma's Chief Accounting Officer, Louise Kooij, plans to sell $7.4 million in shares, likely tied to her upcoming departure from the company.
Key Events · Ownership and Investor Activity · NAMS
-
CAO Files Intent to Sell Shares
Louise Kooij, Chief Accounting Officer, filed a Form 144 to sell 210,000 ordinary shares, valued at approximately $7.4 million.
-
Sale Linked to Departure
This intent to sell follows the company's announcement on April 24, 2026, that Ms. Kooij will depart effective August 31, 2026. The shares are from stock option exercises.
-
Adds to Insider Distribution Trend
This transaction contributes to a net insider distribution of over $36 million in open-market sales over the past 90 days, as noted in recent insider activity.
Analysis · NAMS · Life Sciences
Chief Accounting Officer Louise Kooij has filed a Form 144 indicating her intent to sell approximately $7.4 million worth of ordinary shares. This filing follows the company's announcement on April 24, 2026, that Ms. Kooij will depart effective August 31, 2026. The sale, which involves shares acquired through stock option exercise, contributes to a broader trend of insider distribution observed over the past 90 days.
At the time of this filing, NAMS was trading at $36.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $16.79 to $42.21. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.